These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 37371615)

  • 1. Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario.
    Bianconi A; Palmieri G; Aruta G; Monticelli M; Zeppa P; Tartara F; Melcarne A; Garbossa D; Cofano F
    Biomedicines; 2023 May; 11(6):. PubMed ID: 37371615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
    Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
    J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of glioblastoma: Recent advances and future prospects.
    Yuan B; Wang G; Tang X; Tong A; Zhou L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
    Suryawanshi YR; Schulze AJ
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma.
    Rivera M; Bander ED; Cisse B
    World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Immunotherapeutic Strategies for the Treatment of Glioblastoma.
    Dapash M; Castro B; Hou D; Lee-Chang C
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
    Wang C; Yu M; Zhang W
    Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
    Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
    Front Immunol; 2020; 11():594271. PubMed ID: 33224149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
    Neagu MR; Reardon DA
    Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
    Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy Resistance in Glioblastoma.
    Wang EJ; Chen JS; Jain S; Morshed RA; Haddad AF; Gill S; Beniwal AS; Aghi MK
    Front Genet; 2021; 12():750675. PubMed ID: 34976006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
    Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
    Front Immunol; 2022; 13():867154. PubMed ID: 35603195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.